David Pollard has 30 years’ experience in diverse industrial bioprocess development for a range of therapeutics, including novel mAbs, peptides, anti-infectives, biocatalysts, and more recently, cell therapies.

Between 1995 and 2017, David led process development teams for early and late-stage CMC pipeline teams and provided contributions to multiple INDs and BLAs for Biologics and Vaccines development at Merck & Co. Inc.
David has experience at Kite Pharma, Tessera Tx, and now heads a division of Sartorius corporate research focusing on advancements in bioprocessing.